Gobind Singh

Immunic Inc’s (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst: Gobind Singh initiated coverage of Immunic with a Market Outperform rating and...